Paper Details

  1. Home
  2. Paper Details

Ethambutol plus isoniazid compared with rifampicin plus isoniazid in antituberculosis continuation treatment.

Author: AllanG W, LeesA W, SmithJ, TyrrellW F

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Continuation treatment with ethambutol plus isoniazid was as effective and acceptable as rifampicin plus isoniazid in treating tuberculosis, and was less costly.
Paper Details　
Original Abstract of the Article :
Patients with bacteriologically positive pulmonary tuberculosis were treated initially for an average of three and a half months with isoniazid, rifampicin, and ethambutol and then a total of one year's treatment was completed with either rifampicin plus isoniazid (R+I) or with ethambutol plus isoni...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(77)92439-4

データ提供：米国国立医学図書館（NLM）

Ethambutol Plus Isoniazid: An Effective and Cost-Effective Treatment for Tuberculosis

This study, published in the British Journal of Diseases of the Chest, compares the effectiveness and cost-effectiveness of two continuation treatment regimens for tuberculosis (TB). The authors investigated the use of ethambutol plus isoniazid (E+I) versus rifampicin plus isoniazid (R+I) in patients who had initially received a three-and-a-half-month course of isoniazid, rifampicin, and ethambutol. Their analysis revealed that continuation treatment with E+I was as effective as that with R+I, with no relapses observed in either group. Furthermore, E+I was significantly less costly than R+I, making it a more cost-effective option for TB treatment.

Ethambutol Plus Isoniazid: A Cost-Effective Alternative for TB Treatment

This research provides compelling evidence for the efficacy and cost-effectiveness of E+I as a continuation treatment regimen for TB. The study suggests that E+I can be a viable alternative to the more expensive R+I regimen, particularly in resource-limited settings. The authors emphasize the importance of considering cost-effectiveness in selecting appropriate treatment regimens for TB, ensuring that patients receive effective treatment while minimizing the financial burden.

Navigating the Desert of TB Treatment

This research highlights the importance of finding cost-effective treatment options for TB, particularly in resource-limited settings. Just as a camel navigates the desert seeking water and sustenance, researchers are constantly searching for ways to improve TB treatment outcomes while minimizing the financial burden. This study provides a promising example of how research can lead to cost-effective treatment options, ensuring that patients receive effective care while minimizing the financial strain on healthcare systems.

Dr.Camel's Conclusion

This research offers a valuable insight into the vast desert of TB treatment options. The study demonstrates that E+I is as effective as R+I, but significantly less costly. Just as a camel adapts to the harsh desert environment, healthcare professionals must adapt their practices to find cost-effective solutions that ensure effective treatment while minimizing the financial burden on patients and healthcare systems.
Date :
  1. Date Completed 1977-07-29
  2. Date Revised 2019-06-10
Further Info :

Pubmed ID

68331

DOI: Digital Object Identifier

10.1016/s0140-6736(77)92439-4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.